content top

Long-term Outcomes of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cell Transplantation for Retinal Degeneration from Two Phase I/II Trials

Long-term Outcomes of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cell Transplantation for Retinal Degeneration from Two Phase I/II Trials ABSTRACT Purpose: To summarize long-term safety data and clinical outcomes of two prospective phase I/II studies assessing safety and tolerability of human Embryonic Stem Cell (hESC) derived retinal pigment epithelial (MA09-hRPE) cell transplantation in patients with atrophic...

Read More

Rate of Vitrectomy in the Fellow Eye of Patients Undergoing Primary Diabetic Vitrectomy

Ashish G. Sharma, MD (Detroit, MI), Dean Eliott, MD (Los Angeles, CAI) PURPOSE: To determine the incidence and timing of fellow eye vitrectomy in patients undergoing primary diabetic vitrectomy. METHODS: A retrospective study was done on 351 consecutive patients who underwent primary diabetic vitrectomy by one vitreoretinal surgeon at the Kresge Eye Institute. Patients were followed for an average of two years. The primary vitrectomies were...

Read More

Use of Perfluorocarbon Liquid During Diabetic Vitrectomy

Janice C. Law, MD (Detroit, MI), Dean Eliott, MD (Los Angeles, CA) PURPOSE: The use of perfluorocarbon liquid (PFCL) has facilitated the treatment of complex retinal detachments. The purposes of this study were to evaluate the indications for PFCL use and the anatomic and functional outcome after PFCL use during pars plana vitrectomy for proliferative diabetic retinopathy. METHODS: Retrospective review of 520 consecutive diabetic...

Read More

Reoperation after Diabetic Vitrectomy: Rate, Indications, Visual Outcomes, and Complications in an Urban Academic Medical Center

http://www.evrs.eu/medias/2006/congress/Reoperation-after-Diabetic-Vitrectomy:-Rate,-Indications,-Visual-Outcomes,-and-Complications-in-an-Urban-Academic-Medical-Center.swf Julie L. Gasperini, MD (Detroit, MI), Dean Eliott, MD (Los Angeles, CA) PURPOSE: To identify the rate, indications, visual outcomes, and complications in patients requiring reoperation(s) for the sequelae of proliferative diabetic retinopathy. METHODS: Retrospective...

Read More

The I-vation Sustained Release Drug Delivery System and Intravitreal Implant

Eugene de Juan, Jr., MD (San Francisco, CA),* Robert L. Avery, MD (Santa Barbara, CA), Herbert L. Cantrill, MD (Minneapolis, MN), Pravin U. Dugel, MD (Phoenix, AZ), Dean Eliott, MD (Los Angeles, CA), Charlene Anderson, (Irvine, CA)* PURPOSE: The I-Vation sustained drug delivery system was designed to provide controlled delivery of therapeutics to the back of the eye in a platform that balances minimally invasive implantation, sustained...

Read More

Three-year Results of a Multicenter Clinical Trial of the Fluocinolone Acetonide Intravitreal Implant to Treat Diabetic Macular Edema

http://www.evrs.eu/medias/2006/congress/Three-year-Results-of-a-Multicenter-Clinical-Trial-of-the-Fluocinolone-Acetonide-Intravitreal-Implant-to-Treat-Diabetic-Macular-Edema.swf Dean Eliott, MD (Los Angeles, CA),* Brian Levy, OD, MS (Rochester, NY),* Timothy L. Comstock, OD, MS (Rochester, NY)* PURPOSE: This 4-year prospective, multicenter, randomized, controlled study is being conducted to investigate the safety and  efficacy of a...

Read More
content top